Insilico Medicine ("Insilico"), a clinical-stage, generative AI-driven drug discovery company, today announced the ...
The Phase 1b trial consisted of 24 patients with Parkinson’s disease, who received twice-weekly dosing of either HER-096 or placebo over a four-week period. The trial’s exploratory biomarker program ...
Data published in Scientific Reports confirms a low-burden visual evoked potential (VEP) assessment can be employed across multiple clinical trial sites as an objective measure of neuroplastic ...
Even though it will likely be another year until the adoption of Wi-Fi 8, also known as IEEE 802.11bn, first router ...
The Phase 1b trial consisted of 24 patients with Parkinson’s disease, who received twice-weekly dosing of either HER-096 or placebo over a four-week period. The trial’s exploratory biomarker program ...
Positive interim efficacy data in 2025 underscore potential of ETX101 as a one-time, disease-modifying medicine for Dravet syndrome –– Internal GMP manufacturing capable of supporting pivotal trial ...
Degrader of cancer protein IDO1 prevents cancer immune suppression by cancer and offers promising strategy to support existing immunotherapies ...
Morse Micro, the world's leading provider of Wi-Fi HaLow semiconductors, today announced the general availability of the HaLowLinktm 2, its next-generation long-range Wi-Fi HaLow platform, now ...
CBeyondTM Phase 2a 26-week extension data update and interim results expected Q1 2026. CBeyond Phase 2a Data Monitoring ...
Floquet control uses time-periodic drives to engineer quantum systems, creating dynamic changes in material properties ...
Many projects on these pages do clever things with video. Whether it’s digital or analogue, it’s certain our community can ...
Controlling light is an important technological challenge—not just at the large scale of optics in microscopes and telescopes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback